Diagnostic markers in synovial fluid during prosthetic loosening after total
knee arthroplasty

doi:10.3969/j.issn.2095-4344.2013.26.005

Abstract

Abstract:

BACKGROUND: Aseptic loosening of the prosthesis is a common complication after total knee arthroplasty. Whether the loosening of the prosthesis has relationship with the levels of tenascin-C, interleukin-6 and tumor necrosis factor is not clear.
OBJECTIVE: To observe the expressions of interleukin-6, tumor necrosis factor α and tenascin-C of the patients with aseptic prosthesis loosening after total knee arthroplasty.
METHODS: Forty-five patients treated with total knee arthroplasty and revision surgery were selected as the experimental group, and 25 patients treated with initial total knee arthroplasty were selected as the control group. In the experimental group, the patients with history of inflammatory arthritis, systemic secondary arthritis infection, autoimmune disease and combined hepatitis, malignant tumors, hormones or immunosuppressants administration were eliminated. Synovial fluid samples of the prostheses in each group were obtained, and the expression of tenascin-C shear variants in synovial fluid was tested with Western-blot. The levels of interleukin-6, tumor necrosis factor α and tenascin-C were analyzed with enzyme-linked
immunosorbent assay.
RESULTS AND CONCLUSION: Western blot results showed the presence of large tenascin-C variants in the synovial fluid of prostheses with loosening. The interleukin-6 and tenascin-C levels in the synovial fluid of prosthesis loosening were approximately three times higher than those in the control group, and tumor necrosis factor α level in the synovial fluid of prosthesis loosening was approximately 2.5 times higher than that in the control group. Levels of tenascin-C including large variant subunits are elevated in synovial fluid of prosthesis loosening, indicating that tenascin-C is a useful novel biochemical marker of prosthesis loosening.

Key words: bone and joint implants, artificial prosthesis, arthroplasty, aseptic loosening, synovial fluid, tenascin-c, interlenkin-6, tumor necrosis factor α, marker, cytokine

CLC Number:

R318

Zhao Xu-hong, Wu Ji, Li Song-lin, Chu Dong. Diagnostic markers in synovial fluid during prosthetic loosening after total
knee arthroplasty[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.26.005.

Figures/Tables 4

References

[1] Ingham E, Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials. 2005;26(11):1271-1286.

[2] Wang CJ, Shi JF, Morgan C, et al. Design and simulation of a femoral component peg in total knee replacement. Key Eng Mater. 2011(450):111-114.

[3] Harris WH. Wear and periprosthetic osteolysis: the problem. Clin Orthop Relat Res. 2001;(393):66-70.

[4] Cobelli N, Scharf B, Crisi GM, et al. Mediators of the inflammatory response to joint replacement devices. Nat Rev Rheumatol. 2011;7(10):600-608.

[5] Bottner F, Wegner A, Winkelmann W, et al. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br. 2007;89(1):94-99.

[6] Konttinen YT, Li TF, Xu JW, et al. Expression of laminins and their integrin receptors in different conditions of synovial membrane and synovial membrane-like interface tissue. Ann Rheum Dis. 1999;58(11):683-690.

[7] Li TF, Xu JW, Santavirta S, et al. Expression of vitronectin and its integrin receptors in the synovial membrane-like interface tissue from aseptic loosening of total hip replacement. J Rheumatol. 2000;27(3):727-734.

[8] Konttinen YT, Li TF, Michelsson O, et al. Expression of tenascin-C in aseptic loosening of total hip replacement. Ann Rheum Dis. 1998;57(10):619-623.

[9] Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum. 1996; 25(4):254-272.

[10] Shao JJ, Jiang Y, Zhang XL, et al. Shanghai Yixue. 2002;25 (S1): 30-32.邵俊杰,蒋垚,张先龙,等.白介素-6和转化生长因子-β1在膝骨关节炎发病中的作用[J].上海医学,2002,25(S1):30-32.

[11] Botha-Scheepers S, Watt I, Slagboom E, et al. Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis. Ann Rheum Dis. 2008;67(8):1165-1169.

[12] Hasegawa M, Sudo A, Nagakura T, et al. Tenascin-C levels in pseudosynovial fluid of loose hip prostheses. Scand J Rheumatol. 200534(6):464-468.

[13] Venn G, Nietfeld JJ, Duits AJ, et al. Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis. Arthritis Rheum. 1993;36(6):819-826.

[14] Li NH, Xue QY, Zhang Y, et al. ZHongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2008;12(33):6546-6549.李宁华,薛庆云,张毅,等.中国6个城市4577名中老年人手骨关节炎流行病学调查[J].中国组织工程研究与临床康复,2008, 12(33): 6546-6549.

[15] Hasegawa M, Hirata H, Sudo A, et al. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol. 2004;31(10): 2021-6.

[16] Schmalzried TP, Jasty M, Harris WH. Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space. J Bone Joint Surg Am. 1992;74(6):849-863.

[17] Grassmé H, Kirschnek S, Riethmueller J, et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science. 2000;290(5491): 527-530.

[18] Zhao JN, Mei XL, Guo T, et al. Zhonghua Chuangshang Guke Zazhi. 2011;13(1):21-24.赵建宁,梅晓亮,郭亭,等.全髋关节置换术后血清白细胞介素6、10与纤维蛋白原表达的特点分析[J].中华创伤骨科杂志, 2011, 13(1):21-24.

[19] Rettig WJ, Erickson HP, Albino AP, et al. Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci. 1994; 107 ( Pt 2):487-497.

[20] Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol. 2004; 19(2):517-525.

[21] Järvinen TA, Jozsa L, Kannus P, et al. Mechanical loading regulates tenascin-C expression in the osteotendinous junction. J Cell Sci. 1999;112 Pt 18:3157-3166.

[22] Chiquet M, Sarasa-Renedo A, Tunç-Civelek V. Induction of tenascin-C by cyclic tensile strain versus growth factors: distinct contributions by Rho/ROCK and MAPK signaling pathways. Biochim Biophys Acta. 2004;1693(3):193-204.

[23] Imai S, Konttinen YT, Jumppanen M, et al. High levels of expression of collagenase-3 (MMP-13) in pathological conditions associated with a foreign-body reaction. J Bone Joint Surg Br. 1998;80(4):701-710.

[24] Takei I, Takagi M, Santavirta S, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints. J Biomed Mater Res. 1999;45(3):175-183.

[25] Syggelos SA, Eleftheriou SC, Giannopoulou E, et al. Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses. J Rheumatol. 2001; 28(6):1319-1329.

[26] Siri A, Knäuper V, Veirana N, et al. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995;270(15): 8650-8654.

[27] Spring J, Beck K, Chiquet-Ehrismann R. Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments. Cell. 1989;59(2):325-334.

[28] Weber P, Zimmermann DR, Winterhalter KH, et al. Tenascin-C binds heparin by its fibronectin type III domain five. J Biol Chem. 1995;270(9):4619-4623.

[29] Day JM, Olin AI, Murdoch AD, et al. Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem. 2004;279(13):12511-12518.

[30] Okamura N, Hasegawa M, Nakoshi Y, et al. Deficiency of tenascin-C delays articular cartilage repair in mice. Osteoarthritis Cartilage. 2010;18(6):839-848.

[31] Nakoshi Y, Hasegawa M, Akeda K, et al. Distribution and role of tenascin-C in human osteoarthritic cartilage. J Orthop Sci. 2010;15(5):666-673.

[32] Sofat N, Robertson SD, Hermansson M, et al. Tenascin-C fragments are endogenous inducers of cartilage matrix degradation. Rheumatol Int. 2012;32(9):2809-2817.